TITLE

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men

AUTHOR(S)
Rask, Eva; Olsson, Tommy; Soderberg, Stefan; Johnson, Owe; Seckl, Jonathan; Holst, Jens Juul; Ahren, Bo; Rask, E; Olsson, T; Söderberg, S; Johnson, O; Seckl, J; Holst, J J; Ahrén, B; Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)
PUB. DATE
September 2001
SOURCE
Diabetes Care;Sep2001, Vol. 24 Issue 9, p1640
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: To investigate whether features of the insulin resistance syndrome are associated with altered incretin responses to food intake.Research Design and Methods: From a population-based study, 35 men were recruited, representing a wide spectrum of insulin sensitivity and body weight. Each subject underwent a hyperinsulinemic-euglycemic clamp to determine insulin sensitivity. A mixed meal was given, and plasma levels of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), as well as insulin, glucagon, and glucose were measured.Results: Insulin resistance was associated with impaired GIP and GLP-1 responses to a mixed meal. The total area under the curve (AUC) of the GIP response after the mixed meal was associated with insulin sensitivity (r = 0.54, P < 0.01). There was a significant difference between the highest and the lowest tertile of insulin sensitivity (P < 0.05). GLP-1 levels 15 min after food intake were significantly lower in the most insulin-resistant tertile compared with the most insulin-sensitive tertile. During the first hour, the AUC of GLP-1 correlated significantly with insulin sensitivity (r = 0.47, P < 0.01). Multiple linear regression analysis showed that insulin resistance, but not obesity, was an independent predictor of these decreased incretin responses.Conclusions: In insulin resistance, the GIP and GLP-1 responses to a mixed meal are impaired and are related to the degree of insulin resistance. Decreased incretin responsiveness may be of importance for the development of impaired glucose tolerance.
ACCESSION #
5090571

 

Related Articles

  • Gastrin: an analytical review. Varro, Andrea; Ardill, Joy ES // Annals of Clinical Biochemistry;Sep2003, Vol. 40 Issue 5, p472 

    The gastric hormone gastrin is produced in multiple forms that vary in their biological properties. In this analytical review, the strategies available for the assay of different gastrins in plasma are considered. Except for research purposes, it is seldom necessary or even desirable to employ...

  • The majority of dorsal spinal cord gastrin releasing peptide is synthesized locally whereas neuromedin B is highly expressed in pain- and itch-sensing somatosensory neurons. Fleming, Michael S.; Ramos, Daniel; Han, Seung Baek; Zhao, Jianyuan; Son, Young-Jin; Luo, Wenqin // Molecular Pain;2012, Vol. 8 Issue 1, p52 

    Background: Itch is one of the major somatosensory modalities. Some recent findings have proposed that gastrin releasing peptide (Grp) is expressed in a subset of dorsal root ganglion (DRG) neurons and functions as a selective neurotransmitter for transferring itch information to spinal cord...

  • Lack of insulin inhibition on insulin secretion in non-diabetic morbidly obese patients. Muscelli, E; Pereira, J A; Lazarin, M A C T; da Silva, C A; Pareja, J C; Saad, M J A // International Journal of Obesity & Related Metabolic Disorders;Jun2001, Vol. 25 Issue 6, p798 

    OBJECTIVE: Insulin inhibition of insulin secretion has been described in normal lean subjects. In this study, we examined whether this phenomenon also occurs in the morbidly obese who often have severe peripheral insulin resistance. SUBJECTS: Twelve obese patients, normotolerant to glucose (8F/4...

  • Gastric inhibitory polypeptide links overnutrition to obesity. Ballinger, A. // Gut;Mar2003, Vol. 52 Issue 3, p319 

    Describes a novel pathway of obesity promotion via gastric inhibitory polypeptide (GIP) and extreme visceral and subcutaneous fat deposition with insulin resistance. High-fat diet fed to mice lacking the GIP receptor; Resistance to obesity of GIP receptor knockout mice.

  • RESPONSE OF THE PYLORUS AND OESOPHAGEAL LIGATED RAT TO GASTRIN AND A RELATED PEPTIDE. Hansky, J. // Australian Journal of Experimental Biology & Medical Science;Aug1968, Vol. 46 Issue 4, p473 

    Evaluates the response of the pylorus and oesophageal ligated rat to gastrin and a related peptide. Comparison of the synthetic pentapeptide and pure gastrin; Indication that the pylorus and oesophageal ligated rat may be a suitable preparation for the bioassay of gastrin and related peptides;...

  • Gastrin.  // Encyclopedic Reference of Molecular Pharmacology;2004, p384 

    This article presents an encyclopedia entry for gastrin. It is a peptide hormone which is synthesized in cells of the mucosa of the gastric antrum and duodenum and secreted into the portal blood. Its main effect is the stimulation secretion of acid by the parietal cells of the stomach. It also...

  • Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance. Strawbridge, Andrew B.; Elmendorf, Jeffrey S.; Mather, Kieren J. // Current Diabetes Reviews;2006, Vol. 2 Issue 3, p317 

    Since the discovery of endothelin peptides in the mid-1980s by Yanigasawa and colleagues, accumulating evidence demonstrates that these peptides may function beyond vasoconstriction. Strong epidemiologic associations between insulin resistance and increased endothelin levels or activity have...

  • Neuropeptides in the Pathogenesis of Obesity-Associated Benign Acanthosis Nigricans. Bernstein, Joel E.; Rothstein, Jeffrey; Soltani, Keyoumars; Levine, Lawrence E. // Journal of Investigative Dermatology;Jan1983, Vol. 80 Issue 1, p7 

    The association of acanthosis nigricans with pituitary tumors and insulin-resistant diabetes suggests that a pituitary peptide may promote papillomatosis and acanthosis characteristic of acanthosis nigricans. Although such a peptide has not been isolated, it may derive by sequential cleavage...

  • Liraglutide effective in treating type 2 diabetes.  // Formulary;Sep2004, Vol. 39 Issue 9, p432 

    Reports that once-daily injections of liraglutide, a long-acting, acylated, glucagons-like peptide 1 analog, have proven to be effective in the treatment of patients with type 2 diabetes. Fasting glucose level; Mean B-cell function; Lack of differences in insulin resistance;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics